{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-001362","form_type":"8-K","ticker":"PROF","cik":"0001628808","company_name":"Profound Medical Corp.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.683176+00:00","generated_at":"2026-05-15T19:41:09.734393+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Profound Medical Q4 revenue $6M (+43% YoY), net loss $8.2M; installed base 78 TULSA-PRO","bullets":["Q4 revenue record $6.0M (+43% YoY); net loss $8.2M ($0.27/sh) vs $4.9M loss year ago.","FY2025 revenue $16.1M (up from $10.7M); net loss $42.6M ($1.41/sh) vs $27.8M loss.","TULSA-PRO installed base 78, pipeline 110; expects ~120 installs by end of 2026.","Dec 2025 financing: $36M US offering + $6.45M Canadian private placement; cash $59.7M.","Board change: Kris Shah resigns, Frank Baylis appointed; Baylis co-founded Baylis Medical (sold for $1.75B)."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-001362","json":"https://secwatch.observer/filing/0001171843-26-001362.json","markdown":"https://secwatch.observer/filing/0001171843-26-001362.md","text":"https://secwatch.observer/filing/0001171843-26-001362.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628808/000117184326001362/0001171843-26-001362-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628808/000117184326001362/f8k_030526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:41:09.734393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}